Skip to main content
OpenTrials
Completed

NCT Number: NCT07461012

Impact of Garlic on the Clinical Outcome in Chronic Hemodialysis Patients

Chronic kidney disease (CKD) is an irreversible condition marked by reduced kidney function or structural abnormalities lasting over three months, affecting a significant portion of the global population. It leads to a cycle of complications including albuminuria, anemia, mineral bone disorders, inflammation, oxidative stress, and accumulation of uremic toxins. These factors contribute to endothelial dysfunction (ED) and elevate the risk of cardiovascular diseases (CVDs), which are the primary cause of death in end stage kidney disease (ESKD) patients, especially those undergoing hemodialysis (HD). Hemodialysis further aggravates systemic inflammation and oxidative stress, increasing levels of cytokines like IL-6, TNF-α, and CRP. Endocan, a proteoglycan secreted by endothelial cells in response to inflammation, is a promising biomarker for ED and CVD risk, with levels that correlate with CKD severity. Garlic (Allium sativum) contains bioactive compounds with proven anti-inflammatory, antioxidant, and endothelial protective effects. This trial was suggested based on a study that has reported that giving 400 mg of garlic extract twice a day for 8 weeks in peritoneal dialysis patients resulted in significant reduction in IL-6, CRP and ESR. This study aims to investigate the effect of Garlic on Endothelial dysfunction and inflammation in chronic hemodialysis patients via assessment of Endocan as an endothelial dysfunction marker and IL-6 as an inflammation marker.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

faculty of pharmacy Ain Shams university

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients aged above 18 years with confirmed diagnosis of CKD.
  • Patients on HD for at least 3 months before enrollment.
  • Patients not participating in other clinical trials.
  • Physically stable.

Exclusion criteria

  • Patients diagnosed with digestive diseases as ileal bypass.
  • Patients with a history of hemorrhagic disorders or taking medications like warfarin.
  • Patients sensitive to garlic.
  • Patients with history of alcohol or drug abuse.
  • Patients receiving other anti-inflammatory medications (e.g. use of vitamin E at a dose higher than 60 IU per day or vitamin C higher than 500 mg per day)

Treatment and study plan

Dried garlic powder (Garlic extract) - Allium sativum.

Dietary Supplement

A tablet containing 300 mg dried garlic powder

Primary outcomes

  1. endocan

    Time frame: 12 weeks

    To evaluate the impact of Garlic on endothelial dysfunction in chronic hemodialysis patients via assessment of Endocan.

  2. interleukin-6

    Time frame: 12 weeks

    To evaluate the impact of Garlic on inflammation in chronic hemodialysis patients via assessment of IL-6 marker.

Secondary outcomes

  1. safety of garlic in CHD patients

    Time frame: 12 weeks

    To evaluate the safety of Garlic in patients on HD by monitoring any adverse effects that may occur.

  2. (KDQOL™-36) questionnaire

    Time frame: 12 weeks

    To evaluate the impact of Garlic on quality of life in CHD patients

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 10, 2026
Registry last updated
Mar 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.